StockData
ACTUNasdaqPharmaceutical PreparationsFiscal year ends December 31

ACTUATE THERAPEUTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.60−0.01 (-0.99%)

Close on Oct 19, 2026

Market cap
$14.30M
P/E (TTM)
–
Dividend yield
–

SEC filings

30 of Actuate Therapeutics's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Quarterly report10-QJun 30, 2026Aug 14, 2026SEC EDGAR
Current report8-KJul 15, 2026Jul 17, 2026SEC EDGAR
Current report8-KMay 21, 2026May 22, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 14, 2026SEC EDGAR
Current report8-KMay 11, 2026May 11, 2026SEC EDGAR
Current report8-KMay 1, 2026May 6, 2026SEC EDGAR
Proxy statementDEF 14AMay 21, 2026Apr 6, 2026SEC EDGAR
Annual report10-KDec 31, 2025Mar 26, 2026SEC EDGAR
Current report8-KJan 12, 2026Jan 12, 2026SEC EDGAR
Current report8-KNov 28, 2025Nov 28, 2025SEC EDGAR
Current report8-KNov 21, 2025Nov 21, 2025SEC EDGAR
Quarterly report10-QSep 30, 2025Nov 13, 2025SEC EDGAR
Current report8-KSep 10, 2025Sep 10, 2025SEC EDGAR
Quarterly report10-QJun 30, 2025Aug 14, 2025SEC EDGAR
Current report8-KJun 25, 2025Jun 26, 2025SEC EDGAR
Current report8-KMay 31, 2025Jun 5, 2025SEC EDGAR
Current report8-KMay 31, 2025Jun 2, 2025SEC EDGAR
Current report8-KMay 22, 2025May 23, 2025SEC EDGAR
Quarterly report10-QMar 31, 2025May 15, 2025SEC EDGAR
Current report8-KMay 6, 2025May 6, 2025SEC EDGAR
Proxy statementDEF 14AMay 22, 2025Apr 8, 2025SEC EDGAR
Current report8-KMar 27, 2025Mar 28, 2025SEC EDGAR
Annual report10-KDec 31, 2024Mar 13, 2025SEC EDGAR
Current report8-KFeb 7, 2025Feb 7, 2025SEC EDGAR
Current report8-KDec 17, 2024Dec 17, 2024SEC EDGAR
Quarterly report10-QSep 30, 2024Nov 13, 2024SEC EDGAR
Current report8-KNov 12, 2024Nov 12, 2024SEC EDGAR
Quarterly report10-QJun 30, 2024Sep 24, 2024SEC EDGAR
Current report8-KAug 19, 2024Aug 19, 2024SEC EDGAR
Current report8-KAug 14, 2024Aug 14, 2024SEC EDGAR